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ABSTRACT
Background: Hypercapnia is associated with diaphragm muscle dysfunction 
that causes a reduction of diaphragmatic force generated for a constant elective myo-
graphic activity. No published data are available concerning hypercapnic depression of 
diaphragmatic contractility during dibutyryl cyclic adenosine monophospate (DBcAMP) 
administration.
Objective: The aim of this study was to assess the effects of DBcAMP on hyper-
capnic depression of diaphragmatic contractility in pentobarbital-anesthetized dogs.
Methods: This experimental study was conducted from July to December 2008 
at the Department of Anesthesiology, Institute of Clinical Medicine, University of 
Tsukuba, Tsukuba, Japan. Adult (aged >5 years) mongrel dogs weighing 10 to 15 kg 
were randomly divided into 3 equal groups. Hypercapnia (80–90 mm Hg) was in-
duced with 10% carbon dioxide added to the inspired gas. When hypercapnia was es-
tablished, group 1 was infused with low-dose DBcAMP (0.05 mg/kg/min); group 2 
was infused with high-dose DBcAMP (0.2 mg/kg/min); and group 3 received placebo 
(saline). Study drug was administered intravenously for 60 minutes. Diaphragmatic 
contractility was assessed by transdiaphragmatic pressure (Pdi) at baseline, induction 
of hypercapnia, and study drug administration.
Results: Twenty-one dogs were divided into 3 groups of 7. There were no 
significant differences observed at baseline. In the presence of hypercapnia, Pdi (mean 
[SD], cm H2O) at low- (20-Hz) and high-frequency (100-Hz) stimulation was signifi-
cantly decreased from baseline in each group (all, P = 0.001). In groups 1 and 2, Pdi at 
both stimuli was significantly increased during DBcAMP administration compared 
with hypercapnia-induced values (group 1: 20-Hz, 13.5 [2.2] vs 15.0 [2.4], respec-
tively, P = 0.001, 100-Hz, 21.2 [1.6] vs 22.5 [1.6], P = 0.001; group 2: 20-Hz, 13.7 
[1.4] vs 19.2 [1.7], P = 0.001, 100-Hz, 21.0 [2.4] vs 27.2 [2.5], P = 0.001). The Pdi 
at both stimuli during DBcAMP administration was significantly higher in group 2 
than in group 1 (20-Hz, 19.2 [1.7] vs 15.0 [2.4], P = 0.001, 100-Hz, 27.2 [2.5] vs 
22.5 [1.6], P = 0.003). In group 3, Pdi did not significantly change in regard to either 
stimulus from hypercapnia-induced values.
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Conclusion: DBcAMP, in a dose-dependent manner, was associated with im-
proved hypercapnic depression of diaphragmatic contractility in these pentobarbital-
anesthetized dogs. (Curr Ther Res Clin Exp. 2010;71:154–161) © 2010 Excerpta Medica 
Inc.
Key words: muscle, diaphragm, contractility, hypercapnia, dibutyryl cyclic 
adenosine monophosphate (DBcAMP).
INTRODUCTION
Patients with chronic airway obstruction, who are hypercapnic, have decreased perfor-
mance of respiratory muscles, especially the diaphragm.1 In healthy human subjects, 
hypercapnia is associated with diaphragm muscle dysfunction, which causes a reduc-
tion in the diaphragmatic force generated for a constant elective myographic activity.2
Several drugs have been assessed for their effects on diaphragmatic contractility dur-
ing hypercapnia.3,4 Aminophylline, neostigmine, milrinone, and olprinone have been 
effective for improving hypercapnic depression of diaphragmatic contractility; however, 
isoproterenol did not affect diaphragm muscle dysfunction induced by hypercapnia.3,4
Dibutyryl cyclic adenosine monophosphate (DBcAMP), a derivative of cAMP, is more 
membrane permeable and less susceptible to intracellular hydrolysis than cAMP.5 It 
has been reported to improve cardiac performance in dogs through its inotropic and 
chronotropic effects6 and has been used for the treatment of congestive heart failure.7
Like cardiac contraction, diaphragmatic contractility of fatigued canine diaphragm 
was found to be augmented by DBcAMP.8 However, based on a search of MEDLINE 
and EMBASE (terms: muscle, diaphragm, contractility, hypercapnia, and DBcAMP; years: 
1985–2008), no published data are available concerning hypercapnic depression of 
diaphragmatic contractility during DBcAMP administration.
The purpose of this experimental study was to assess the effects of DBcAMP on the per-
formance of the diaphragm depressed by hypercapnia in pentobarbital-anesthetized dogs.
MATERIALS AND METHODS
This study was conducted at the Department of Anesthesiology, Institute of Clinical 
Medicine, University of Tsukuba, Tsukuba, Japan, from July to December 2008. The 
protocol was approved by the university’s animal research committee, and animal care 
was conducted in accordance with guidelines for ethical animal research.4
Healthy, adult (aged >5 years) mongrel dogs weighing 10 to 15 kg (provided by 
Animal Guidance Center, Mashiko, Japan) were used in the study. Animals were ran-
domly assigned, using a computer-generated random-number list, to 1 of 3 groups: 
group 1 received low-dose DBcAMP (0.05 mg/kg/min); group 2 received high-dose 
DBcAMP (0.2 mg/kg/min); and group 3 received placebo (saline).
Animal preparation was similar to that previously described.4 Briefly, anesthesia 
was maintained with pentobarbital 2 mg/kg/h IV. This dose has been found to have 
no effect on diaphragmatic contractility.8 No muscle relaxants were used. Each dog’s 
trachea was intubated, and ventilation was mechanically controlled with a mixture of 
oxygen (O2) and air (fraction of inspired O2, 0.4) to maintain partial pressure of O2 in 
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arterial blood (PaO2) >100 mm Hg, partial pressure of carbon dioxide in arterial 
blood (PaCO2) 35 to 40 mm Hg, and partial pressure of hydrogen in arterial blood 
(pHa) 7.35 to 7.45. The right femoral artery was cannulated for monitoring arterial 
blood pressure. The right femoral vein was cannulated for administering maintenance 
fluids (lactated Ringer’s solution 10 mg/kg/h) and pentobarbital. The left femoral 
vein was cannulated to administer the study drug. Rectal temperature was monitored 
continuously and maintained at 36.5°C to 37.5°C using a heating pad.
Transdiaphragmatic pressure (Pdi) was measured as previously described.4 Briefly, 
2 thin-walled latex balloons were used: 1 positioned in the stomach and 1 in the 
middle third of the esophagus. Balloons were connected to a differential pressure 
transducer (TP604T, Nihon Koden, Tokyo, Japan) and an amplifier (model 1257, 
Nihondenki San-ei, Tokyo, Japan). Phrenic nerves were exposed bilaterally at the neck, 
and stimulating electrodes were placed around them. Supramaximal electrical stimuli 
(10–15 V) of 0.1-millisecond duration were applied for 2 seconds at low- (20-Hz) and 
high-frequency (100-Hz) stimulation. Diaphragmatic contractility was evaluated by 
measuring the maximal Pdi generated by test stimuli after airway occlusion at func-
tional residual capacity (FRC). Electrical activity of the diaphragm was recorded by 
using 2 pairs of fishhook electrodes, and its signal was rectified and integrated with an 
integrator with a time constant of 0.1 second. This was regarded as the integrated elec-
trical activity of the crural (Edi-cru) and costal (Edi-cost) parts of the diaphragm.
Dogs were allowed to stabilize for ≥30 minutes before study start. Baseline measure-
ments of heart rate (HR), mean arterial pressure (MAP), pHa, PaCO2, PaO2, Pdi, Edi-cru, 
and Edi-cost were recorded in each group. Hypercapnia (PaCO2 80–90 mm Hg) was 
produced by adding 10% CO2 to the inspired gas. Hypercapnia was established at 
2 hours after the initiation of CO2 administration. At that point, group 1 was infused 
with low-dose DBcAMP (0.05 mg/kg/min); group 2 was infused with high-dose 
DBcAMP (0.2 mg/kg/min); and group 3 received placebo (saline). An infusion pump 
was used to administer the study drug intravenously for 1 hour. HR, MAP, pHa, 
PaCO2, PaO2, Pdi, Edi-cru, and Edi-cost were then measured. Saline was administered 
at a rate of 10 mL/h. Percentage changes from baseline in Edi-cru (%Edi-cru) and 
Edi-cost (%Edi-cost) were determined.4 
Statistical Analysis
An a priori power analysis indicated that 7 dogs per group would be required to 
detect a significant difference in Pdi to each stimulus between baseline, hypercapnia, 
and treatment periods with a power (1-β) of 0.8 (α = 0.05). Values are reported as 
mean (SD). Statistical analyses were performed by using ANOVA for repeated mea-
surements, followed by the Bonferroni-Dunn test for multiple comparisons and t test, 
where appropriate. P < 0.05 was considered statistically significant. All statistical 
analyses were conducted using SPSS version 8.0 (SPSS Inc., Chicago, Illinois).
RESULTS
Twenty-one adult mongrel dogs (15 males and 6 females; mean [SD] weight, 
12.5 [1.5] kg) were included in the study; 7 dogs were assigned to each treatment 
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group. No significant differences in HR, MAP, pHa, PaCO2, PaO2, Pdi, %Edi-cru, 
and %Edi-cost were observed between the 3 groups at baseline (Tables I and II).
When hypercapnia was established, HR (mean [SD], bpm) and MAP (mean [SD], 
mm Hg) were significantly increased compared with baseline in each group (group 1: 
HR, 149 [3] vs 140 [3], P = 0.001, MAP, 130 [6] vs 121 [6], P = 0.001; group 2: 
HR, 148 [4] vs 139 [5], P = 0.001, MAP, 131 [7] vs 121 [5], P = 0.001; group 3: 
HR, 151 [7] vs 140 [6], P = 0.001, MAP, 134 [5] vs 123 [6], P = 0.001) (Table I). 
After the administration of DBcAMP, HR was significantly increased in groups 1 and 
2 and MAP was significantly decreased in group 2 compared with values obtained 
during hypercapnia (group 1: HR, 155 [3] vs 149 [3], P = 0.001; group 2: HR, 166 
[5] vs 148 [4], P = 0.001, MAP, 117 [6] vs 131 [7], P = 0.001).
By administering CO2 to induce hypercapnia, a significant increase in PaCO2
(mean [SD], mm Hg) and a significant decrease in pHa (mean [SD]) were observed in 
each group (group 1: PaCO2, 85.0 [3.5] vs 37.4 [1.9], P = 0.001, pHa, 7.12 [0.03] 
vs 7.41 [0.01], P = 0.001; group 2: PaCO2, 84.7 [3.9] vs 36.5 [0.7], P = 0.001, pHa, 
7.13 [0.02] vs 7.42 [0.01], P = 0.001; group 3: PaCO2, 84.4 [3.3] vs 36.2 [0.4], P = 
0.001, pHa, 7.13 [0.01] vs 7.40 [0.01], P = 0.001) (Table I). No significant differ-
ence in PaO2 was observed.
In the presence of hypercapnia, Pdi (mean [SD], cm H2O) at low- (20-Hz) and 
high-frequency (100-Hz) stimulation significantly decreased from baseline in each 
group (group 1: 20 Hz, 15.1 [2.6] vs 13.5 [2.2], P = 0.001, 100 Hz, 23.2 [1.6] vs 
21.2 [1.6], P = 0.001; group 2: 20 Hz, 15.2 [1.4] vs 13.7 [1.4], P = 0.001, 100 Hz, 
23.1 [2.4] vs 21.0 [2.4], P = 0.001; group 3: 20 Hz, 15.0 [2.3] vs 13.4 [2.7], P = 
0.001, 100 Hz, 23.1 [2.8] vs 20.8 [2.9], P = 0.001) (Table II). In group 3, Pdi to 
each stimulus did not change from hypercapnia-induced values. In groups 1 and 2, 
during DBcAMP administration, Pdi at both stimuli frequencies significantly in-
creased compared with the hypercapnia-induced values (group 1: 20-Hz, 13.5 [2.2] 
vs 15.0 [2.4], P = 0.001, 100-Hz, 21.2 [1.6] vs 22.5 [1.6], P = 0.001; group 2: 20-Hz, 
13.7 [1.4] vs 19.2 [1.7], P = 0.001, 100-Hz, 21.0 [2.4] vs 27.2 [2.5], P = 0.001). 
The Pdi at both stimuli frequencies during DBcAMP administration was signifi-
cantly higher in group 2 than that in group 1 (20 Hz, 19.2 [1.7] vs 15.0 [2.4], P = 
0.001; 100 Hz, 27.2 [2.5] vs 22.5 [1.6], P = 0.004). No changes in %Edi-cru and 
%Edi-cost were observed throughout the experiment in any group (Table II).
DISCUSSION
The major findings of this study were as follows: (1) when hypercapnia was established, 
Pdi at 20-Hz and 100-Hz stimulation significantly decreased compared with baseline 
values; and (2) DBcAMP was associated with increased Pdi at both stimuli frequencies 
in a dose-dependent manner. These findings are suggestive of the positive inotropic ef-
fects of DBcAMP on the diaphragmatic contractility in patients during hypercapnia, 
which may contribute to the development of diaphragm muscle dysfunction.
Diaphragmatic contractility is assessed by force-frequency characteristics9–11 and 
is often evaluated by the measurement of Pdi, which is affected by the length and 
geometry of the diaphragm during precontracted conditions.12 A major determinant 
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of the diaphragmatic length and geometry is lung volume. Conceivably, the changes 
in Pdi may be secondary to changes in the end-expiratory lung volume. In this study, 
however, the airway was occluded at the end-expiratory lung volume (ie, FRC) during 
measurements.
Hypercapnia impairs diaphragmatic contractility in vivo13 and in vitro.14 Previous re-
search has found hypercapnic depression of diaphragmatic contractility in pentobarbital-
anesthetized dogs.4 In that study, Pdi at 20- and 100-Hz stimulation significantly 
decreased from baseline (all, P = 0.001) in the presence of hypercapnia. As we have 
stated in the past,4 the mechanism by which hypercapnia decreases diaphragmatic 
Table I.  Changes in hemodynamics and arterial blood gas tensions in pentobarbital-
anesthestized dogs at baseline, hypercapnia induction, and treatment with 
dibutyryl cyclic adenosine monophosphate (DBcAMP). All values are reported 
as mean (SD).
Variables Group Baseline Hypercapnia Treatment
Hemodynamics
  HR, bpm 1 140 (3) 149 (3)* 155 (3)*†‡
2 139 (5) 148 (4)* 166 (5)*†‡§
3 140 (6) 151 (7)* 149 (5)*
  MAP, mm Hg 1 121 (6) 130 (6)* 126 (6)
2 121 (5) 131 (7)* 117 (6)†]
3 123 (6) 134 (5)* 132 (6)*
Arterial gas tensions
  pHa 1 7.41 (0.01) 7.12 (0.03)* 7.14 (0.01)*
2 7.42 (0.01) 7.13 (0.02)* 7.14 (0.01)*
3 7.40 (0.01) 7.13 (0.01)* 7.14 (0.01)*
  PaCO2, mm Hg 1 37.4 (1.9) 85.0 (3.5)* 84.4 (2.2)*
2 36.5 (0.7) 84.7 (3.9)* 85.4 (3.1)*
3 36.2 (0.4) 84.4 (3.3)* 84.7 (3.1)*
  PaO2, mm Hg 1 150.0 (2.2) 152.5 (1.9) 151.5 (2.5)
2 151.7 (7.0) 151.4 (8.6) 152.0 (8.5)
3 151.1 (1.4) 151.2 (3.4) 152.4 (2.8)
HR = heart rate; group 1 = DBcAMP 0.05 mg/kg/min; group 2 = DBcAMP 0.2 mg/kg/min; group 3 = 
placebo (saline); MAP = mean arterial pressure; pHa = partial pressure of hydrogen in arterial blood; 
PaCO2 = partial pressure of carbon dioxide in arterial blood; PaO2 = partial pressure of oxygen in arterial 
blood.
*P = 0.001 versus baseline.
†  P = 0.001 versus hypercapnia.
‡  P = 0.001 versus control (group 3).
§  P = 0.002 versus group 1.
]P = 0.025 versus group 1.
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contractility is unknown, but there is a possibility that an alteration of muscle pH 
may be related to a decrease in the affinity of troponin for calcium, an increase in the 
binding of calcium by the sarcoplasmic reticulum, or a decrease in the rate of glycolysis 
and, therefore, adenosine triphosphate resynthesis.15–17
In the present study, we found that Pdi at 20- and 100-Hz stimulation signifi-
cantly increased from hypercapnia-induced values with an infusion of DBcAMP (0.05 
or 0.2 mg/kg/min). The exact mechanism by which DBcAMP improves diaphrag-
Table II.  Changes in transdiaphragmatic pressure (Pdi) and integrated electrical activity 
of the diaphragm (Edi) in pentobarbital-anesthestized dogs at baseline, hyper-
capnia, induction, and treatment with dibutyryl cyclic adenosine monophos-
phate (DBcAMP). All values are reported as mean (SD).
Variables Group Baseline Hypercapnia Treatment
Pdi, cm H2O
  20-Hz stimulation 1 15.1 (2.6) 13.5 (2.2)* 15.0 (2.4)†‡
2 15.2 (1.4) 13.7 (1.4)* 19.2 (1.7)†‡§
3 15.0 (2.3) 13.4 (2.7)* 13.5 (3.1)*
  100-Hz stimulation 1 23.2 (1.6) 21.2 (1.6)* 22.5 (1.6)†‡
2 23.1 (2.4) 21.0 (2.4)* 27.2 (2.5)†‡]
3 23.1 (2.8) 20.8 (2.9)* 21.0 (2.9)*
Edi-cru, %
  20-Hz stimulation 1 100.0 (0.0) 100.0 (4.6) 98.8 (3.0)
 2 100.0 (0.0) 98.5 (2.4) 99.2 (1.8)
 3 100.0 (0.0) 98.7 (7.5) 98.8 (3.0)
  100-Hz stimulation 1 100.0 (0.0) 98.8 (1.9) 99.4 (1.5)
 2 100.0 (0.0) 99.4 (1.5) 99.4 (1.5)
 3 100.0 (0.0) 99.2 (1.6) 99.6 (1.2)
Edi-cost, %
  20-Hz stimulation 1 100.0 (0.0) 99.0 (2.6) 99.0 (2.6)
 2 100.0 (0.0) 99.2 (1.8) 99.2 (1.8)
 3 100.0 (0.0) 99.2 (2.5) 99.2 (2.5)
  100-Hz stimulation 1 100.0 (0.0) 99.2 (1.8) 99.2 (1.8)
 2 100.0 (0.0) 98.8 (1.9) 99.4 (1.5)
 3 100.0 (0.0) 99.4 (1.5) 99.4 (1.5)
Group 1 = DBcAMP 0.05 mg/kg/min; group 2 = DBcAMP 0.2 mg/kg/min; group 3 = placebo (saline); 
Edi-cru = integrated electrical activity of the crural part of the diaphragm; Edi-cost = integrated electrical 
activity of the costal part of the diaphragm.
* P = 0.001 versus baseline.
† P = 0.001 versus hypercapnia.
‡ P = 0.001 versus group 3.
§ P = 0.003 versus group 1.
]P = 0.004 versus group 1.
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matic contractility during hypercapnia is not known. However, it has been suggest-
ed that DBcAMP may have a direct positive effect on diaphragmatic contractility.8
DBcAMP was associated with increased intracellular cAMP, which promotes the ac-
tivation of calcium ion (Ca2+) transport from the sarcoplasmic reticulum.18 Therefore, 
DBcAMP may increase the diaphragmatic contractility by influencing Ca2+ transport 
across the cell membrane.
No significant changes in %Edi-cru and %Edi-cost were observed in any group. 
This suggests that hypercapnia and DBcAMP (0.05 or 0.2 mg/kg/min) administra-
tion do not affect the electrical activity of the diaphragm.
Signs of CO2 retention are tachycardia and hypertension.
19 When hypercapnia 
(80–90 mm Hg) was established in this study, HR and MAP significantly increased 
from baseline. With an infusion of DBcAMP, HR increased significantly and MAP 
decreased significantly from that obtained during hypercapnia in groups 1 and 2. 
These hemodynamic changes during DBcAMP administration are consistent with 
those we found previously.8
The data described from this experiment provides information on the improvement 
in hypercapnic depression of diaphragmatic contractility associated with DBcAMP 
administration. However, this must be considered within the context of the study’s 
limitations. First, the effective dose of DBcAMP for diaphragm muscle function is 
unknown. The recommended dose of DBcAMP for the improvement of myocardial 
performance is between 0.05 and 0.2 mg/kg/min.20 Previously, we examined the dia-
phragm muscle function during fatigue by administering DBcAMP 0.2 mg/kg/min 
in dogs.8 Second, the exact mechanism by which DBcAMP affected hypercapnic de-
pression of diaphragmatic contractility was not studied. However, there is a possibil-
ity that DBcAMP may increase the diaphragmatic contractility by influencing Ca2+
transport across the cell membrane.18 Regardless of the unknown mechanism of ac-
tion, our results have therapeutic implications for diaphragm muscle dysfunction as-
sociated with hypercapnia. Third, our sample size was small. However, when a power 
analysis was performed, a total of 7 dogs in each group were found to be sufficient to 
detect a significant difference with α of 0.05 and a power of 80%. Lastly, the study 
was not blinded. Further studies should consider these limitations.
CONCLUSION
DBcAMP, in a dose-dependent manner, was associated with improved hypercapnic 
depression of diaphragmatic contractility in pentobarbital-anesthetized dogs. 
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